“Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)”
The purpose of this study is to to assess the safety and tolerability of pirfenidone 2403 mg/day for the treatment of RA-associated interstitial lung disease.
Drug - Pirfenidone
Pirfenidone three times daily (2403 mg) for 52 weeks
Drug - Placebo
Placebo three times daily for 52 weeks
Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients With Rheumatoid Arthritis Interstitial Lung Disease (TRAIL1)